EUVIMEDEUVIMED entdecken
Crossref

Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis

Yu Nishida iD, Shuhei Hosomi iD, Koji Fujimoto, Yumie Kobayashi, Rieko Nakata, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuhiro Fujiwara

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izaf302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Yu Nishida und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Pyrimidines, Piperidines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Patients with ulcerative colitis (UC) have an elevated thromboembolic risk. The comparative risks associated with advanced therapies (ADTs) remain unclear.

Methods

In this retrospective cohort study, we utilized the Japanese Medical Data Vision claims database to assess patients with UC who initiated treatment with tumor necrosis factor (TNF) inhibitors, vedolizumab, or tofacitinib. We evaluated the cumulative incidence and hazard ratios (HRs) for venous thromboembolisms (VTEs), cardiovascular events (CVEs), and major adverse cardiovascular events (MACEs). The tofacitinib dose was modeled as a time-varying covariate.

Results

In total, 8125 TNF inhibitor users, 1218 tofacitinib users, and 2469 vedolizumab users were analyzed. Compared with TNF inhibitors, vedolizumab was associated with a lower risk of VTE (HR ,50, 95% CI 0.30-0.81) and CVE (HR 0.47, 95% CI, 0.27-0.81), with no difference in MACE. Tofacitinib 5 mg and 10 mg administration twice daily (BID) showed no significant differences vs TNF inhibitors, though point estimates were lower at 5 mg and higher at 10 mg. Concomitant 5-aminosalicylic acid was associated with a lower incidence of VTE.

Conclusions

Vedolizumab demonstrated a favorable thromboembolic and cardiovascular safety profile compared with TNF inhibitors, whereas tofacitinib did not increase the risk at either dose. Concomitant 5-aminosalicylic acid may have a preventive effect against VTE. These findings may aid therapeutic decision-making for UC patients with elevated thrombotic risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePyrimidinesPiperidinesAntibodies, Monoclonal, HumanizedTumor Necrosis Factor InhibitorsVenous ThromboembolismHumansFemaleRetrospective StudiesMaleMiddle AgedAdultIncidenceJapanRisk FactorsAgedFollow-Up StudiesCardiovascular Diseases

Stichwörter der Autor:innen

cardiovascular eventsmedical claims databasetofacitinibtumor necrosis factor inhibitorsulcerative colitisvedolizumabvenous thromboembolism

Substanzen

tofacitinibvedolizumabPyrimidinesPiperidinesAntibodies, Monoclonal, HumanizedTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

ORCID-Profile: Yu Nishida, Shuhei Hosomi

Zitieren

APA

Nishida, Y., Hosomi, S., Fujimoto, K., Kobayashi, Y., Nakata, R., Maruyama, H., Ominami, M., Nadatani, Y., Fukunaga, S., Otani, K., Tanaka, F., & Fujiwara, Y. (2026). Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf302

Vancouver

Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, et al. Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf302

BibTeX
@article{Nishida2026,
  author = {Nishida, Yu and Hosomi, Shuhei and Fujimoto, Koji and Kobayashi, Yumie and Nakata, Rieko and Maruyama, Hirotsugu and Ominami, Masaki and Nadatani, Yuji and Fukunaga, Shusei and Otani, Koji and Tanaka, Fumio and Fujiwara, Yasuhiro},
  title = {Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izaf302}
}
Kostenlos starten →